GLATIRAMER ACETATE

( DrugBank: Glatiramer, Acetate / KEGG DRUG: - )

3 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	189
96	クローン病	1

告示番号	疾患名（ページ内リンク）	臨床試験数
156	レット症候群	2

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 10 of 189 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05688436 (ClinicalTrials.gov)	September 24, 2021	9/1/2023	A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate	Pregnancy Outcomes in Women Exposed to Diroximel Fumarate	Multiple Sclerosis	Drug: Diroximel Fumarate;Biological: Alemtuzumab;Drug: Fingolimod;Drug: Glatiramer acetate;Biologica ...	Biogen	NULL	Recruiting	18 Years	49 Years	Female	825		United States
2	EUCTR2020-004505-32-DE (EUCTR)	06/07/2021	25/05/2021	Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - ...	An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Asses ...	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Produ ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	236	Phase 3	France;Spain;Germany;United Kingdom;Italy
3	NCT04079088 (ClinicalTrials.gov)	June 30, 2021	3/9/2019	Study to Evaluate Oral BIIB061 Added to Interferon-beta1 (IFN-ß1) or Glatiramer Acetatein Relapsing ...	A Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Phase 2 Study to Evalu ...	Relapsing Multiple Sclerosis	Drug: Placebo;Drug: BIIB061;Biological: Interferon-beta1;Drug: Glatiramer acetate	Biogen	NULL	Not yet recruiting	18 Years	55 Years	All	300	Phase 2	NULL
4	EUCTR2020-004505-32-FR (EUCTR)	09/06/2021	26/04/2021	Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - ...	An Open-Label, Rater-Blind, Randomized, Multi-Center, Parallel-Arm, Active-Comparator Study to Asses ...	Multiple Sclerosis MedDRA version: 20.0;Level: PT;Classification code 10048393;Term: Multiple sclero ...	Trade Name: Kesimpta Product Name: ofatumumab Product Code: OMB157 INN or Proposed INN: OFATUMUMAB Produ ...	Novartis Pharma AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	236	Phase 3	France;Germany
5	EUCTR2020-005752-38-DE (EUCTR)	18/03/2021	19/01/2021	An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants wit ...	An open-label multicenter study to assess response to SARS-CoV-2 modRNA vaccines in participants wit ...	secondary progressive multiple sclerosis (SPMS);Therapeutic area: Diseases [C] - Nervous System Dise ...	Trade Name: Mayzent 2 mg Filmtabletten Product Name: Mayzent 2 mg Filmtabletten Product Code: BAF312A I ...	Novartis Pharma GmbH	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 4	Germany
6	EUCTR2018-000284-93-EE (EUCTR)	10/12/2019	02/10/2019	A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlle ...	A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlle ...	Relapsing forms of Multiple Sclerosis (RMS) MedDRA version: 20.1;Level: PT;Classification code 10028 ...	Product Name: GA Depot INN or Proposed INN: GLATIRAMER ACETATE	Mapi Pharma Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	960	Phase 3	United States;Serbia;Belarus;Estonia;Ukraine;Russian Federation;Israel;Montenegro;Czech Republic;Mac ...
7	EUCTR2018-000284-93-BG (EUCTR)	15/11/2019	08/10/2019	A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlle ...	A multinational, multicenter, randomized, Phase III, double blind, parallel group, placebo controlle ...	Relapsing forms of Multiple Sclerosis (RMS) MedDRA version: 20.1;Level: PT;Classification code 10028 ...	Product Name: GA Depot INN or Proposed INN: GLATIRAMER ACETATE	Mapi Pharma Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1000	Phase 3	United States;Belarus;Estonia;Ukraine;Russian Federation;Israel;Georgia;Bulgaria;Montenegro;Moldova, ...
8	NCT04121221 (ClinicalTrials.gov)	September 19, 2019	8/10/2019	A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot i ...	A Phase III Study in Subjects With Relapsing Forms of Multiple Sclerosis (RMS) to Asses Efficacy, Sa ...	Multiple Sclerosis, Relapsing-Remitting	Drug: GA Depot;Other: Placebo	Mapi Pharma Ltd.	NULL	Active, not recruiting	18 Years	55 Years	All	1016	Phase 3	United States;Belarus;Bosnia and Herzegovina;Bulgaria;Estonia;Georgia;Israel;Moldova, Republic of;Ru ...
9	EUCTR2017-005129-18-IT (EUCTR)	08/01/2019	26/03/2018	Clinical trial to evaluate the effectiveness and safety of IFN beta-1a (IFN beta-1a), injected once ...	Multi-centre, randomised, open label pragmatic trial to compare the effectiveness and safety of inte ...	Relapsing-remitting multiple sclerosis with paediatric onset MedDRA version: 20.1;Level: PT;Classifi ...	Trade Name: Copaxone 40 mg/ml solution for injection, pre-filled syringe INN or Proposed INN: Glatira ...	Università degli Studi Aldo Moro	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	142	Phase 3	Italy
10	NCT05762003 (ClinicalTrials.gov)	January 1, 2019	9/2/2023	Czech Pharmaco-epidemiological Study on Disease Modifying Drugs	Czech Pharmaco-epidemiological Real World Data Study Focused on Effectiveness of Different Disease M ...	Multiple Sclerosis	Drug: interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fi ...	IMPULS Endowment Fund	NULL	Completed	N/A	N/A	All	17478		Czechia

First Previous1 2 3 4 5…19Next Last

96. クローン病

臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00731172 (ClinicalTrials.gov)	September 2008	6/8/2008	A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in C ...	A Pilot Single Center,Randomized,Double Blind Placebo Controlled Study to Assess the Safety,Tolerabi ...	Crohns Disease	Drug: glatiramer acetate;Drug: placebo	Tel-Aviv Sourasky Medical Center	Teva Pharmaceutical Industries;Given Imaging Ltd.	Recruiting	18 Years	70 Years	Both	50	Phase 2	Israel

First Previous1Next Last

156. レット症候群

臨床試験数 : 44 / 薬物数 : 61 - (DrugBank : 23) / 標的遺伝子数 : 57 - 標的パスウェイ数 : 83

trials per page:

Showing 1 to 2 of 2 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02023424 (ClinicalTrials.gov)	January 2014	23/12/2013	An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetateon Girls W ...	An Open Label, Exploratory Study to Investigate the Treatment Effect og Glatiramer Acetate(Copaxone ...	Rett Syndrome	Drug: Glatiramer Acetate (Copaxone®)	Sheba Medical Center	NULL	Recruiting	6 Years	15 Years	Female	10	Phase 1	Israel
2	NCT02153723 (ClinicalTrials.gov)	August 2013	26/5/2014	Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)	Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)	Rett Syndrome	Drug: Glatiramer Acetate	Montefiore Medical Center	Rett Syndrome Research Trust	Completed	10 Years	N/A	Female	10	Phase 2	United States

First Previous1Next Last